Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis

Abstract

This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather than therapeutic failure. Common intermittent microdosing schedules may allow greater receptor recovery between administrations and may consequently test a different chronic pharmacology. The analogy with conventional antidepressants is deliberately limited: selective serotonin reuptake inhibitors do not act through 5-HT2A down-regulation alone, but their delayed effects also involve adaptive responses to repeated serotonergic perturbation. The hypothesis arose from one uncontrolled personal observation and is not presented as evidence of efficacy, causality, or safety. It generates falsifiable predictions and can be tested by directly comparing daily, intermittent, cumulative-dose-matched, and placebo schedules using 5-HT2A receptor imaging or functional proxies, repeated measures of acute tolerance, clinical outcomes, pharmacokinetic sampling, and washout assessments. Alternative or complementary mechanisms involving 5-HT1A, 5-HT2C, TrkB-BDNF signaling, learning, and expectancy must be separated experimentally. Long-term safety, including unresolved possible 5-HT2B-mediated valvular risk, requires specific investigation. This manuscript is a research hypothesis, not a clinical dosing recommendation.